Why Stealth BioTherapeutics Shares Are Surging Today?

  • Stealth BioTherapeutics Corp MITO presented new SBT-272 preclinical data demonstrating functional improvement in upper motor neurons with TDP-43 pathology.
  • TDP-43 pathology plays a significant role in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). 
  • The data were presented at the Keystone Neurodegeneration Symposium.
  • A Phase 1 study to evaluate the safety and tolerability of SBT-272 in healthy volunteers is underway.
  • Read Next: Stealth Bio Posts Disappointing Elamipretide Data From Mid-Stage Geographic Atrophy Study.
  • The data demonstrated that SBT-272 significantly improved mitochondrial structural integrity and motility in TDP-43 mutant (A315T)-expressing upper motor neurons. 
  • These enhancements in mitochondrial health were associated with improved axon outgrowth, a key indicator of improved neuronal health. 
  • The effect of SBT-272 on axon outgrowth was superior to edaravone (approved for the treatment of ALS) and Amylyx Pharmaceuticals Inc AMLX AMX0035 (under FDA review). 
  • Chronic in vivo administration of SBT-272 reduced upper motor neuron degeneration and neuroinflammation in the motor cortex of the prp‐hTDP‐43A315T‐UeGFP mouse model of ALS. 
  • Price Action: MITO shares are up 6.60% at $0.27 on the last check Wednesday.

Posted In: BiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving